Abozymes Completes Seed Financing Round To Fund Development Of Technology To Enable Universal Organ Transplants And Blood Transfusions

ABOzymes Biomedical Inc., today announced it has completed a substantially upsized seed financing. The funds will be used to further develop its ground-breaking proprietary platform that enables a world where a patient’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions.